Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International (NASDAQ: DYAI) released its Q1 2024 results, reporting a net loss of $2.01 million or $(0.07) per share, compared to a net loss of $0.96 million or $(0.03) per share a year ago. Revenue for the quarter decreased to $335,000 from $934,000 in Q1 2023. Cash and equivalents stood at $12.1 million as of March 31, 2024.
Key advancements include positive Phase 1 results for DYAI-100, a COVID-19 booster vaccine, and multiple collaborations on vaccine and antibody projects. The company also expanded its work in animal health and alternative proteins sectors.
Strategic partnerships were formed to develop rabies vaccines and alternative proteins. The financial standing was bolstered by a $6.0 million convertible note. Leadership changes include Patrick Lucy as Board Chairman and Joe Hazelton as COO.
Dyadic International, a biotechnology company, will be attending several industry and investor events in May 2024. The events include PEGS Boston, EFHutton Annual Global Conference, ECI Vaccine Technology IX, and Lytham Spring 2024 Investor Conference. Management members will be present to discuss the company's innovative microbial platforms and biopharmaceutical products.
Dyadic International, Inc. will report its financial results for the first quarter of 2024 and host a corporate update conference call on May 14, 2024. The company focuses on large-scale protein manufacture for vaccines, therapeutics, and non-pharmaceutical applications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.